- Home
- VKTX vs APLS Comparison
VKTX vs APLS Comparison
Compare VKTX & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- APLS
- Stock Information
- Founded
- VKTX 2012
- APLS 2009
- Country
- VKTX United States
- APLS United States
- Employees
- VKTX N/A
- APLS N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- VKTX Health Care
- APLS Health Care
- Exchange
- VKTX Nasdaq
- APLS Nasdaq
- Market Cap
- VKTX 2.8B
- APLS 2.2B
- IPO Year
- VKTX 2015
- APLS 2017
- Fundamental
- Price
- VKTX $28.14
- APLS $18.25
- Analyst Decision
- VKTX Buy
- APLS Buy
- Analyst Count
- VKTX 12
- APLS 19
- Target Price
- VKTX $84.00
- APLS $37.39
- AVG Volume (30 Days)
- VKTX 3.9M
- APLS 1.9M
- Earning Date
- VKTX 07-23-2025
- APLS 07-31-2025
- Dividend Yield
- VKTX N/A
- APLS N/A
- EPS Growth
- VKTX N/A
- APLS N/A
- EPS
- VKTX N/A
- APLS N/A
- Revenue
- VKTX N/A
- APLS $775,839,000.00
- Revenue This Year
- VKTX N/A
- APLS $1.01
- Revenue Next Year
- VKTX N/A
- APLS $22.14
- P/E Ratio
- VKTX N/A
- APLS N/A
- Revenue Growth
- VKTX N/A
- APLS 48.04
- 52 Week Low
- VKTX $18.92
- APLS $16.10
- 52 Week High
- VKTX $81.73
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- VKTX 55.39
- APLS 48.67
- Support Level
- VKTX $25.80
- APLS $17.15
- Resistance Level
- VKTX $28.80
- APLS $18.60
- Average True Range (ATR)
- VKTX 1.65
- APLS 0.70
- MACD
- VKTX 0.11
- APLS -0.04
- Stochastic Oscillator
- VKTX 86.93
- APLS 45.25
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.